Sodium Lauryl Sulfate Increases the Efficacy of a Topical Formulation of Foscarnet against Herpes Simplex Virus Type 1 Cutaneous Lesions in Mice

JOCELYNE PIÈRET,1 ANDRÉ DÉSORMEAUX,1 HÉLÈNE CORMIER,1 JULIE LAMONTAGNE,1 PIERRETTTE GOURDE,1 JULIANNA JUHÁSZ,2 AND MICHEL G. BERGERON1*

Centre de Recherche en Infectiologie1 and Faculté de Pharmacie,2 Université Laval, Québec, Québec, Canada

Received 12 January 2000/Returned for modification 7 March 2000/Accepted 25 May 2000

The influence of sodium lauryl sulfate (SLS) on the efficacies of topical gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous infection has been evaluated in mice. A single application of the gel formulation containing 3% foscarnet given 24 h postinfection exerted only a modest effect on the development of herpetic skin lesions. Of prime interest, the addition of 5% SLS to this gel formulation markedly reduced the mean lesion score. The improved efficacy of the foscarnet formulation containing SLS could be attributed to an increased penetration of the antiviral agent into the epidermis. In vitro, SLS decreased in a concentration-dependent manner the infectivities of herpesviruses for Vero cells. SLS also inhibited the HSV-1 strain F-induced cytopathic effect. Combinations of foscarnet and SLS resulted in subadditive or subadditive effects, depending on the concentration used. Foscarnet in phosphate-buffered saline decreased in a dose-dependent manner the viability of cultured human skin fibroblasts. This toxic effect was markedly decreased when foscarnet was incorporated into the polymer matrix. The presence of SLS in the gel formulations did not alter the viabilities of these cells. The use of gel formulations containing foscarnet and SLS could represent an attractive approach to the treatment of herpetic mucocutaneous lesions, especially those caused by acyclovir-resistant strains.

Recurrent herpes labialis and herpes genitalis represent the most common clinical manifestations associated with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections, respectively. The frequencies of recurrent herpetic infections in the U.S. population are estimated to be 50 to 70% for HSV-1 and 23% for HSV-2 (59). In immunocompetent individuals, recurrences are self-limiting, but in immunocompromised patients, untreated mucocutaneous herpetic infections can be chronic and progressive. Acyclovir and penciclovir and their respective prodrugs valaciclovir and famciclovir are the drugs of choice for the treatment of herpetic infections. However, the emergence of drug-resistant virus mutants after long-term treatment of immunocompromised patients with acyclovir led to an increased number of acyclovir treatment failures in this population (7, 10, 17, 34, 45, 51). The recovery of acyclovir-resistant HSV among clinical isolates from patients with normal immunity has not been associated with the progression of clinical disease (5, 13, 29). However, acyclovir-resistant HSV has been recovered more frequently from immunocompromised patients and has resulted in locally progressive mucocutaneous lesions (5, 13, 18, 19, 29, 31, 34). The majority of acyclovir-resistant HSV clinical isolates are also cross-resistant to penciclovir (39, 60). Alternative therapy for mucocutaneous herpetic infections includes foscarnet (trisodium phosphonoformate), a pyrophosphate analogue that inhibits HSV DNA polymerase without activation by viral thymidine kinase. Foscarnet is thus effective for the treatment of acyclovir-resistant herpetic infections (25, 38). However, the currently available treatments, either topical or systemic, have only moderate effects on the clinical course of recurrent herpes labialis and herpes genitalis in immunocompetent hosts (6, 9, 43, 44, 46, 48, 50, 55).

Topical formulations for the treatment of herpetic mucocutaneous infections have several potential advantages over formulations used systemically for drug delivery, including targeting of the drug to the specific sites of infection, higher tissue drug levels, reduced side effects, lower treatment costs, and better convenience (49). However, the efficacy of topical formulations is often limited by the poor ability of antiviral agents to penetrate into the skin. The stratum corneum or horny layer constitutes an effective barrier against the penetration of substances into the skin. This layer consists of corneocytes embedded in a double-layered lipid matrix composed of free sterols, free fatty acids, triglycerides, and ceramides (12, 15, 16, 21, 27). Thus, the use of skin penetration enhancers could represent a convenient strategy to increase the penetration of antiviral agents into the skin and therefore their efficacies against herpetic lesions.

Sodium lauryl sulfate (SLS), an anionic surfactant, possesses skin penetration enhancer properties and enhances penetration into the skin by increasing the fluidity of epidermal lipids (20, 30, 36, 37). The increase in lipid fluidity below the applied site may allow SLS to diffuse in all directions including the radial path (36). SLS could thus increase intraepidermal drug delivery without increasing transdermal delivery. Furthermore, SLS is a potent inhibitor of the infectivities of various HSV strains at quite low concentrations and under very mild conditions (24, 42). Taken together, these properties suggest that SLS could be a potential candidate for use in combination with antiviral agents in topical formulations.

Previous studies from our laboratory have demonstrated that the efficacy of 5% acyclovir incorporated into a polymer...
composed of polyoxypropylene and polyoxyethylene was more effective than that of the commercial 5% acyclovir ointment (Zovirax) in reducing the development of herpetic skin lesions in mice after a single application given 24 h postinfection (40). The improved efficacy of the gel formulation of acyclovir was attributed to the semisemiosmic character of the polymer, which allows a more efficient drug penetration into the skin. However, foscarnet incorporated into this polymer had no marked effect under the same treatment regimen. In the present study, we have evaluated whether the incorporation of the skin penetration enhancer SLS into the polymer formulation containing foscarnet could increase the penetration of this drug into the skin and, thereby, its efficacy against HSV-1 cutaneous lesions in hairless mice.

**MATERIALS AND METHODS**

**Materials.** Foscarnet (trisodium phosphonofumarate) and SLS were obtained from Sigma Chemical Co. (St. Louis, Mo.). [14C]foscarnet was obtained from Moravek (Brea, Calif.).

**Cell lines.** Vero cells (African green monkey kidney cells; American Type Culture Collection, Rockville, Md.) were cultivated in Eagle’s minimum essential medium (EMEM; Canadian Life Technologies, Burlington, Ontario, Canada) supplemented with sodium bicarbonate (0.22%), penicillin-streptomycin (100 U/ml), 1-glutamine (2 mM), and 5% heat-inactivated fetal bovine serum (FBS; Canadian Life Technologies). Human skin fibroblasts (from a healthy control; American Type Culture Collection) were cultivated in EMEM containing sodium bicarbonate (0.22%), penicillin-streptomycin (100 U/ml), 1-glutamine (2 mM; 1-glutamine [2 mM], 1-glutamine [200 mM], and 10% FBS. Cultures were maintained at 37°C in a 5% CO2 atmosphere.

**Viruses.** HSV-1 strain F (American Type Culture Collection), HSV-2 strain 6, which is resistant to acyclovir (thymidine kinase deficient), and HSV-2 strain 15589, which is resistant to foscarnet (kindly provided by Guy Boivin, Centre de Recherche en Infectiologie, Laval University, Sainte-Foy, Que´bec, Canada), were propagated in Vero cells in complete EMEM containing 2% FBS. Human skin fibroblasts (from a healthy control; American Type Culture Collection) were cultivated in EMEM containing sodium bicarbonate (0.22%), penicillin-streptomycin (100 U/ml), 1-glutamine (2 mM; 1-glutamine [2 mM], 1-glutamine [200 mM], and 10% FBS. Cultures were maintained at 37°C in a 5% CO2 atmosphere.

**Preparation of topical formulations.** In vivo studies, we have used a polymer composed of polyoxypropylene and polyoxyethylene suspended in phosphate buffer (200 mM; pH 6.0) at a concentration of 18% (w/v). We selected a pH of 6.0 to correspond to the pH of the skin. Foscarnet and/or SLS was added to the polymer powder and was then dissolved in phosphate buffer (200 mM; pH 6.0). The final concentration of foscarnet was 3% (w/v; i.e., 100 mM), while that of SLS was 1.5, or 10% (w/v; i.e., 35, 174, or 347 mM, respectively). For cell culture studies, the formulations were prepared in phosphate-buffered saline (PBS; pH 7.4).

**Pharmacokinetics.** Confluent Vero cells seeded in 24-well plates were infected with approximately 100 PFU of HSV-1 strain F in 0.5 ml of EMEM–2% FBS for 2 h at 37°C in a 5% CO2 atmosphere. Cell sheets were washed twice with fresh culture medium, overlaid with 0.5 ml of 0.6% SeaPlaque agarose (Mandel Scientific, Laval, Que´bec, Canada) in EMEM–2% FBS containing concentrations of foscarnet and/or SLS, and incubated for 2 days at 37°C. The cells were then fixed with 10% formaldehyde in PBS for 20 min, washed with deionized water, and stained with 0.05% methylene blue. Virus-induced cytopathic effect was evaluated by determination of the numbers of PFUs.

**Analysis of drug combination effect.** The inhibitory effects of combinations of drugs on the HSV-1 strain F-induced cytopathic effect was examined with combinations of various concentrations of the test compounds in a checkerboard design. The drug combination effect was analyzed by the isobologram method as described previously (4). In this analysis, the 50% effective dose (ED50) was used to calculate the fractional inhibitory concentration (FIC). When the minimum FIC of the combined compounds (i.e., FIC1 + FIC2) is equal to 1.0, the combination is assumed to act in an additive manner; if it is between 0.5 and 1.0, the combination acts synergistically, and when it is less than 0.5, it acts antagonistically. On the other hand, when the minimum FIC index is between 1.0 and 2.0, the combination is subantagonistic, and when it is greater than 2.0, the combination is antagonistic.

**Virus inactivation assay.** Prior to infection, HSV-1 strain F, HSV-2 strain 6, or HSV-2 strain 15589 was suspended in PBS or diluted with different concentrations of SLS in PBS and preincubated for 1 h at 37°C in a water bath. Confluent Vero cells, seeded in 24-well plates, were then infected with pretreated viruses (approximately 50 PFU/500 μl) and the plates were immediately centrifuged (750 × g for 45 min at 20°C). Virus was removed by aspiration, and the cell sheets were overlaid with 0.5 ml of EMEM–2% FBS containing 0.6% SeaPlaque agarose. The plates were incubated for 2 days at 37°C in a 5% CO2 atmosphere. The cells were then fixed, washed, and stained as described above. Virus inactivation was evaluated from the determination of the numbers of PFUs.

**Cytotoxicities of foscarnet and SLS.** Vero cells, seeded at midconfluency in 24-well cell culture plates (Corning), were overlaid with 0.5 ml of EMEM–2% FBS containing 0.6% SeaPlaque agarose. The plates were incubated for 2 days at 37°C in a 5% CO2 atmosphere. Afterward, the cell sheets were washed twice with EMEM–5% FBS and cellular viabilities was determined with a tetrazolium salt (MTS) method which in the presence of phenazine methosulfate is reduced by living cells to yield a formazan product that can be assayed colorimetrically (8).

**Cytotoxicities of gel formulations.** Briefly, a semiconfluent monolayer of cultured human skin fibroblasts has been deposited on 0.4-μm cell culture inserts (Millipore Products Divisions, Bedford, Mass.) in six-well plates. The test compounds, foscarnet and/or SLS, prepared in PBS or incorporated in the gel formulation prepared in PBS, were deposited on top of the cells. The culture medium (EMEM–10% FBS) was added below the insert and was in close contact with cells. This experimental design allowed the elimination of potential interference from the interaction of FBS with the tested compounds. After incubation for 24 h at 37°C, the cells were washed with PBS and their viabilities were evaluated as described above.

**Animal model.** Female hairless mice (SKH1; age, 5 to 6 weeks; Charles River Breeding Laboratories Inc., St-Constant, Quebec, Canada) were anesthetized by intraperitoneal injection of a mixture containing 70% of ketamine hydrochloride (Rogar/STB Inc., Montr´eal, Que´bec, Canada) and 11.5 mg of xylazine (Miles Canada Inc., Etoibioke, Ontario, Canada) per kg of body weight. The virus was inoculated on the lateral side of the body in the left lumbar skin area. The skin was scratched six times in a crossed-hatch pattern with a 27-gauge needle held vertically. A viral suspension (5 × 107 PFU/50 μl) was rubbed for 10 to 15 s on the scarified skin area with a cotton-tipped applicator saturated with EMEM–2% FBS. The scarified area was protected with a corn cushion (Schering-Plough Canada Inc., Mississauga, Ontario, Canada), which was held on the mouse back with surgical tape. Three animals (Surgical Tape; 3M, St. Paul, Minn.) were housed per cage and observed daily.

**Treatments.** A single application of the topical formulations was given 24 h after infection (i.e., prior to the apparition of the zosteriform rash). Briefly, the tape that closed the aperture of the corn cushion was removed, and 15 μl of one of the topical formulations was applied to the scarified area. The aperture of the corn cushion was closed with surgical tape to avoid rapid removal of the drug by the mice and prevent accidental systemic treatment that could occur if the topical liquids reached the treated lesions. The corn cushions were removed approximately 24 h after application of the topical formulations. The efficacies of the different formulations were evaluated from the mean lesion scores, according to criteria that we have described previously (40, 42), vital titters in skin samples, and survival of animals. No blind evaluations between treatment groups were undertaken in this study.

**In vivo skin penetration studies.** In vivo skin penetration studies were designed to compare the influence of SLS in the polymer matrix on the penetration of foscarnet into unaffected and infected skin tissues. Hairless mice were cutaneously with HSV-1 strain F in order to get a fully developed zosteriform rash. On day 5 postinfection, a corn cushion was placed at the inoculation site of the infected mice. A corn cushion was also placed on the left lumbar skin area of control uninfected mice. Fifteen microliters of 5% foscarnet alone or in combination with 5% SLS incorporated into the gel formulation, or 1.8 μl of 14C-labeled foscarnet, was deposited into the aperture of the corn cushion as described above. Twenty-four hours following treatment, the mice were killed and blood was withdrawn, placed in heparinized tubes, and centrifuged (10,000 × g for 3 min at 4°C). The patches were then removed carefully and the test area was cleaned with a humidified cotton-tipped applicator and then dried with a sterile gauze to remove the formulations remaining from the application. The test area was stripped with tape 15 times by using an approxi mately 1-cm length of adhesive tape to remove the stratum corneum. Thereafter, the skin was excised (approximately 2 cm2), and the epidermis and dermis were separated by heat splitting at 60°C in a water bath. The tissues were then treated with Tissue Solubilizer-450 (BTS-450; Beckman Instruments Inc., Irvine, Calif.), decolorized with hydrogen peroxide, and neutralized with glacial acetic acid. The radicles were associated with tape strips, plasma, and each tissue sample was determined with a liquid scintillation counter (Beckman Instruments Canada Inc., Mississauga, Ontario, Canada).

**Statistical analysis.** The analysis of variance test, followed as appropriate by a t test with Fisher’s corrections for multiple simultaneous comparisons. The significance of the differences in the mortality rates between infected control and drug-treated groups was evaluated by a chi-square test. The significance of the differences between the AUCs of foscarnet in the stratum corneum and stratum granulosum between the different concentrations in the epidermis and dermis was evaluated by an unpaired t test. The significance of the differences between the viabilities of cells incubated with foscarnet in PBS or gel formulations were evaluated by an unpaired Student t test (Statview+SE Software; Abacus Concepts, Berkeley, Calif.). A P value of less than 0.05 was considered statistically significant.
RESULTS

Efficacies of topical formulations. Figure 1 shows the time evolution of the mean lesion scores for untreated infected mice and infected mice treated 24 h postinfection with a single application of the gel alone or with gel formulations containing foscarnet and/or SLS. Among the untreated infected mice, no pathological signs of cutaneous lesions were seen during the first 4 days following infection, and only the scarified area remained apparent (Fig. 1A). On day 5, mice developed herpetic skin lesions in the form of vesicles distant from the inoculation site. On day 7, these vesicles became coalescent to form a zoster-like lesion along the affected dermatome. Mean lesion scores were maximal on day 8 and decreased thereafter from days 10 to 15 because of the spontaneous healing of cutaneous lesions in the surviving mice. Treatment with the polymer alone exerted no therapeutic effect. The topical formulation containing 3% foscarnet exerted a modest but significant effect on the development of herpetic skin lesions compared to the effect of no treatment and treatment with the gel alone (Table 1). Treatment of the mice with the polymer containing 10% SLS significantly reduced the mean lesion score, but treatment of the mice with formulations containing 1 or 5% SLS did not (Fig. 1B to D). Treatment of the mice with the gel containing 1 or 10% SLS in combination with 3% foscarnet gave results similar to those achieved by treatment with the formulation containing 3% foscarnet only. Of prime interest, treatment with the gel formulation containing 3% foscarnet and 5% SLS resulted in a marked and significant reduction in the mean lesion score compared to those for all groups tested. Among the untreated infected mice, 59% of animals died from encephalitis between days 7 and 12, whereas about 80% of mice treated with the gel plus 3% foscarnet, the gel plus 10% SLS, the gel plus 1% SLS, and the gel plus 3% foscarnet and 1% SLS. Treatments were given as a single application 24 h after infection. Values represent the means for 17 animals per group pooled from three independent experiments (5 mice per group for the first experiment and 6 mice per group for the second and third experiments).

![Figure 1](http://aac.asm.org/) Time evolution of the mean lesion scores for hairless mice infected cutaneously with HSV-1 strain F. (A) Mean lesion score for mice treated with the gel alone (○) or with the gel containing 3% foscarnet (●). Untreated infected mice (□) were used as controls. (B) Mean lesion score for mice treated with the gel containing 1% SLS (○) or 3% foscarnet and 1% SLS (●). (C) Mean lesion score for mice treated with the gel containing 5% SLS (○) or 3% foscarnet and 5% SLS (●). (D) Mean lesion score for mice treated with the gel containing 10% SLS (○) or 3% foscarnet and 10% SLS (●). Treatments were given as a single application 24 h after infection.

TABLE 1. AUC of the time evolution of the mean lesion scores for mice treated 24 h postinfection with a single application of different gel formulations

<table>
<thead>
<tr>
<th>Treatment</th>
<th>AUC&lt;sup&gt;a&lt;/sup&gt;</th>
<th>P value (compared to the results for the corresponding group)</th>
<th>a</th>
<th>b</th>
<th>c</th>
<th>d</th>
<th>e</th>
<th>f</th>
<th>g</th>
<th>h</th>
<th>i</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) None</td>
<td>32.12 ± 0.97</td>
<td>NS&lt;sup&gt;b&lt;/sup&gt; &lt;0.05 NS &lt;0.05 &lt;0.05 &lt;0.01 &lt;0.05 &lt;0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) Gel alone</td>
<td>32.12 ± 1.18</td>
<td>NS &lt;0.05 NS &lt;0.05 NS &lt;0.01 &lt;0.05 &lt;0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(c) Gel + 3% foscarnet</td>
<td>26.24 ± 1.86</td>
<td>&lt;0.05 &lt;0.05 NS NS NS &lt;0.01 NS NS NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(d) Gel + 1% SLS</td>
<td>27.94 ± 2.73</td>
<td>NS NS NS NS &lt;0.01 NS NS NS NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(e) Gel + 3% foscarnet + 1% SLS</td>
<td>26.24 ± 2.35</td>
<td>&lt;0.05 &lt;0.05 NS NS NS &lt;0.01 NS NS NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(f) Gel + 5% SLS</td>
<td>29.18 ± 1.85</td>
<td>NS NS NS NS NS &lt;0.01 NS NS NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(g) Gel + 3% foscarnet + 5% SLS</td>
<td>14.38 ± 2.46</td>
<td>&lt;0.01 &lt;0.01 &lt;0.01 &lt;0.01 &lt;0.01 &lt;0.01 &lt;0.01 &lt;0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(h) Gel + 10% SLS</td>
<td>26.24 ± 1.80</td>
<td>&lt;0.05 &lt;0.05 NS NS NS &lt;0.01 NS NS NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(i) Gel + 3% foscarnet + 10% SLS</td>
<td>24.65 ± 1.93</td>
<td>&lt;0.01 &lt;0.01 NS NS NS &lt;0.01 NS NS NS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Values are means ± standard errors of the means calculated as [(score on day 4 + score on day 10)/2] + sum of all scores between days 4 and 10.

<sup>b</sup> NS, not significant.
controls. Values represent the means for seven animals per group.

SLS, or the gel plus 3% foscarnet and 1, 5, or 10% SLS survived the infection (P < 0.001) (data not shown). Furthermore, no significant reduction of viral titers in skin samples from the inoculation site and from the lower flank (located between the inoculation site and the ventral midline) was observed following treatment with all the topical formulations tested (data not shown).

Figure 2 shows the time evolution of the mean lesion scores for untreated infected mice and mice treated 24 h postinfection with a single application of buffered solution containing 3% foscarnet (C) or 3% foscarnet plus 5% SLS (D) or with the gel containing 5% SLS (●), 3% foscarnet (○), or 3% foscarnet plus 5% SLS (▲). Untreated infected mice (□) were used as controls. Values represent the means for seven animals per group.

In vivo skin penetration studies. Figure 3 shows the distribution of foscarnet in the skin tissues of uninfected and infected mice 24 h after its topical application either alone or in combination with SLS in the gel formulation. The amount of foscarnet in the stratum corneum tape strips of uninfected mice was significantly higher (P < 0.005) when SLS was incorporated in the polymer matrix. No or negligible amounts of foscarnet were found in the underlying epidermis and dermis of uninfected mice even when SLS was added to the gel formulation. The amount of drug recovered in the skin tissues of infected mice were systematically higher than those detected in uninfected mice. In infected mice, the concentration of foscarnet in the epidermis was higher when SLS was incorporated into the gel formulation, but the variability was high. Conversely, the concentration of foscarnet in the dermis of uninfected and infected mice was not influenced by the presence of SLS. Foscarnet was not recovered in the plasma of uninfected and infected mice (data not shown).

Virus inactivation. Figure 4 shows that pretreatment of wild-type HSV-1 and of acyclovir- and foscarnet-resistant HSV-2 strains with SLS for 1 h at 37°C decreased, in a concentration-dependent manner, their infectivities for Vero cells. Following pretreatment with 25 μM SLS, the infectivities of wild-type HSV-1 and acyclovir- and foscarnet-resistant HSV-2 strains were reduced to 9, 34, and 38% of control values, respectively. A complete loss of the infectivities for all strains tested was obtained following pretreatment of the viruses with 50 μM SLS.

Inhibitory effect. Table 3 shows the inhibitory effect of foscarnet, alone or in combination with SLS, on the HSV-1 strain F-induced cytopathic effect in Vero cells. The ED₅₀ of foscarnet was 74.18 μM. The ED₅₀ decreased to 30.10, 34.40, and 55.24 μM when foscarnet was combined with 12.5, 25, and 37.5 μM SLS, respectively. SLS alone also exerted an inhibitory effect on the HSV-1 strain F-induced cytopathic effect, with an ED₅₀ of 65.30 μM. The ED₅₀ was not modified when SLS was combined with 17 μM foscarnet, but it was decreased to 32.61 and 55.35 μM in the presence of 33 and 50 μM foscarnet, respectively. The inhibitory effects of combinations of both compounds on the virus-induced cytopathic effect were analyzed by the isobologram method. The FIC of SLS plus the FIC of foscarnet were between 0.87 and 1.82 for all combinations, indicating that combinations were subsynergistic to subantagonistic, depending on the concentration used. Figure 5 shows the effect of foscarnet alone or in combination with various concentrations of SLS on the viabilities of Vero cells. Foscarnet decreased the viabilities of Vero cells in a concentration-

---

**TABLE 2. Effects of topical treatments on the development of herpetic cutaneous lesions in mice after a single application 24 h postinfection**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>AUCa</th>
<th>P value (compared to the results for the corresponding group)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td>(a) None</td>
<td>39.42 ± 1.06</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>(b) 3% foscarnet–buffer</td>
<td>25.50 ± 4.23</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>(c) 3% foscarnet + 5% SLS–buffer</td>
<td>27.14 ± 4.58</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>(d) Gel + 5% SLS</td>
<td>26.64 ± 2.76</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>(e) Gel + 3% foscarnet</td>
<td>28.00 ± 2.60</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>(f) Gel + 3% foscarnet + 5% SLS</td>
<td>16.57 ± 4.92</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

a Values are means ± standard errors of the means calculated as [(score on day 4 + score on day 10)/2] + sum of all scores between days 4 and 10.

b NS, not significant.
dependent manner. The 50% cytotoxic concentration (CC\textsubscript{50}) of foscarnet for this cell line was 50 mM. Incorporation of SLS at a concentration up to 100 mM did not potentiate the toxic effect exerted by foscarnet. The CC\textsubscript{50} of SLS for Vero cells was 275 mM (data not shown).

**Cytotoxicities of gel formulations.** Figure 6 shows the influence of foscarnet in PBS or foscarnet incorporated in the polymer prepared in PBS on the viabilities of cultured human skin fibroblasts. Foscarnet also decreased the viabilities of these cells in a concentration-dependent manner. The CC\textsubscript{50} of foscarnet for this cell line was 0.85% (28 mM). Thus, this cell line is susceptible to foscarnet at concentrations approximately two-fold lower than those to which Vero cells are susceptible. Of prime interest, the incorporation of foscarnet into the gel formulation significantly decreased the cellular toxicity of the antiviral agent. Figure 7 shows that SLS in PBS or SLS incorporated into gel formulations containing or not containing 3% foscarnet did not markedly alter the viabilities of fibroblasts even at a concentration of 10% (347 mM).

**TABLE 3. Inhibitory effects of combinations of foscarnet and SLS on HSV-1 strain F-induced cytopathic effect in Vero cells**

<table>
<thead>
<tr>
<th>Formulations</th>
<th>ED\textsubscript{50} (mM)</th>
<th>FIC\textsubscript{SLS} + FIC\textsubscript{PFA}*</th>
<th>Inhibitory effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foscarnet</td>
<td>74.18 ± 4.73</td>
<td>0.87 ± 0.14</td>
<td>Subsynergistic</td>
</tr>
<tr>
<td>Foscarnet + 12.5 mM SLS</td>
<td>30.10 ± 4.52</td>
<td>0.99 ± 0.03</td>
<td>Subsynergistic</td>
</tr>
<tr>
<td>Foscarnet + 25 mM SLS</td>
<td>34.40 ± 0.95</td>
<td>1.59 ± 0.14</td>
<td>Subantagonistic</td>
</tr>
<tr>
<td>Foscarnet + 37.5 mM SLS</td>
<td>55.24 ± 4.55</td>
<td>1.90 ± 0.07</td>
<td>Subsynergistic</td>
</tr>
<tr>
<td>SLS</td>
<td>65.30 ± 2.60</td>
<td>1.82 ± 0.12</td>
<td>Subantagonistic</td>
</tr>
<tr>
<td>SLS + 17 mM foscarnet</td>
<td>63.33 ± 3.95</td>
<td>1.90 ± 0.07</td>
<td>Subsynergistic</td>
</tr>
<tr>
<td>SLS + 33 mM foscarnet</td>
<td>32.61 ± 2.36</td>
<td>1.90 ± 0.07</td>
<td>Subsynergistic</td>
</tr>
<tr>
<td>SLS + 50 mM foscarnet</td>
<td>55.35 ± 3.89</td>
<td>1.90 ± 0.07</td>
<td>Subsynergistic</td>
</tr>
</tbody>
</table>

* Results are means ± standard deviation of three independent experiments. FIC\textsubscript{SLS} and FIC\textsubscript{PFA}, FICs of SLS and foscarnet (PFA), respectively.

**FIG. 3.** (A) Distribution of foscarnet in the tape strips of the stratum corneum of uninfected (open symbols) and infected (filled symbols) mice 24 h after the topical application of the gel containing 3% foscarnet (PFA; ○, ●) or 3% foscarnet and 5% SLS (△, ▲). (B and C) Concentrations of foscarnet in the epidermis and dermis of noninfected (NI) and infected (I) mice, respectively. Values represent the means ± standard errors of the means for six animals per group.

**FIG. 4.** Infectivities of wild-type HSV-1 strain F (□), acyclovir-resistant HSV-2 strain 6 (●), and foscarnet-resistant HSV-2 strain 15589 (▲) pretreated with SLS for Vero cells. Cells were infected with viruses pretreated for 1 h at 37°C with increasing concentrations of SLS prepared in PBS. Infectivity was expressed as the percentage of PFU compared with that for cells treated with the control (to which SLS was not added). Results represent the average of triplicate incubations from one typical experiment of four experiments conducted.

**DISCUSSION**

In the present study, we have evaluated the effect of SLS on the efficacies of topical formulations containing foscarnet against cutaneous HSV-1 infection in hairless mice. Foscarnet and/or SLS was incorporated into a polymer matrix composed of polyoxypropylene and polyoxyethylene. A single application of the gel formulation containing 3% foscarnet given 24 h after infection showed modest efficacy against the development of herpetic skin lesions. The low level of efficacy of the foscarnet formulation can be attributed to the high anionic character of the drug, which limits its intracellular penetration, thereby restricting its efficacy (14). Of prime interest, the addition of 5% SLS to the foscarnet formulation resulted in a marked and significant reduction of the mean lesion score, whereas the addition of 1 or 10% did not improve the efficacy of the formulation containing the drug. In aqueous solutions, surfactants like SLS aggregate to form micelles. The hydrophobic moieties compose the core of the micelles and are shielded from the surrounding solvent by the shell formed by the anionic head groups. The size and polydispersity of SLS micelles increase with the surfactant concentration (2). Several investigators have reported that surfactants induce a concentration-dependent biphasic action with respect to alteration of skin permeability (2, 56). Indeed, at low concentrations, surfactants
crease the permeability of the skin to many substances probably because they penetrate the skin and disrupt the skin barrier function, whereas the permeability of the skin decreased when higher surfactant concentrations (which are generally above the critical micellar concentration) were used. This could perhaps explain why we did not observe an increased efficacy when the SLS concentration was enhanced from 5 to 10%.

The better efficacy of the combination of 3% foscarnet and 5% SLS was observed only when compounds were incorporated into the polymer matrix. We have previously shown that a polymer composed of poloxypolyethylene, a nonionic surfactant, formed micelles which are highly opaque to electrons when observed by electron microscopy (41) and that SLS formed mixed micelles with this polymer (unpublished data). Goldberg and Safrin (23) have also reported a similar behavior for a mixture composed of poloxymethylene glycol and polyoxymethylated nonionic surfactant with SLS. This suggests that complexes or mixed micelles formed by SLS and the polymer may play a role in the better efficacy of the foscarnet formulation. In addition, since the corn cushions were removed approximately 24 h after application of the topical treatments, the efficacy observed may also result from a continuous contact with a depot of the gel formulation over the 24-h period.

Despite the marked efficacy exerted by the formulation containing both 3% foscarnet and 5% SLS on the development of herpetic skin lesions and survival rates, we could not observe any effect of the treatment on viral titers in skin samples. Similarly, treatment of mice with a gel formulation containing 5% acyclovir given only once 24 h postinfection decreased the development of herpetic skin lesions without any effect on viral titers (40). Klein et al. (26) also showed that topical treatment with phosphonoacetic acid started 2 days postinfection reduced the development of skin lesions without affecting significantly the virus titers in skin. Awan et al. (3) also reported that treatment of mice with 0.5% hydrocortisone in a zosteriform infection model with the adoptive transfer of immune cells caused an increase in the viral titers and an extended presence of infectious virus, while they observed a reduction of the clinical signs of cutaneous lesions. In our study, viral replication could be inhibited following topical treatments initiated 24 h after infection. However, because of the progressive decrease of the foscarnet concentration in skin tissues, remaining viruses or a supply of virus coming back from the ganglia may still replicate to reach titers similar to those observed in untreated infected mice on day 5 postinfection. Thackray and Field (52, 53) have described a rebound of infectious virus in tissues following cessation of therapy. In addition, it is well established that the clinical signs of the disease result from both cytolytic virus replication and the inflammatory response triggered by the presence of virus. This suggests that the decrease in the virus content that could occur soon after topical treatment may reduce the effects of one or both factors. However, it is important to mention that treatment of mice with a gel formulation containing 3% foscarnet, given three times daily for 4 days and initiated 24 h after the infection, exerted a marked effect on the development of cutaneous lesions and survival rates, as well as viral titers in skin samples (40).

An important point for consideration in the treatment of mucocutaneous infections is the delivery of adequate amount
of drugs to the site(s) of infection (49). Despite the high degree of variability of foscarnet concentrations, the better efficacy of the polymer formulation containing 3% foscarnet and 5% SLS observed could be attributed to an increased penetration of the drug into the epidermis, which is actually the site of virus localization, as demonstrated by immunoperoxidase staining of viral antigen (41). Patil et al. (36) have reported that SLS diffuses mostly by a radial path when it is applied topically. The mechanism involves an increased lipid fluidity below the applied site, which allows SLS to diffuse rapidly in the radial path without necessarily increasing the amount of drug delivered transdermally. Diffusion by such a radial path may occur for foscarnet in the presence of SLS, leading to a better targeting of sites of viral replication, therefore explaining the better efficacy of this topical formulation. We have already shown that foscarnet concentrations measured in the epidermis and dermis were higher in infected than in uninfected tissues (40). This effect is probably due to the fact that the scarring and the zosteriform lesion led to a loss of integrity of the skin, thereby altering its barrier function. Although we have not measured the penetration of foscarnet into skin at 24 h postinfection, we may assume, on the basis of the observations described above, that the concentration of foscarnet at this time point would also have been higher in skin tissues of infected mice than in those of uninfected control mice due to the lesions induced by the scarring.

Incorporation of SLS into the polymer matrix exerted a modest effect on the development of herpetic cutaneous lesions but significantly increased the survival rate for the mice. Previous studies have demonstrated that the administration of potent polyclonal and monoclonal immunoglobulin G antibodies with high virus neutralizing activities also protects mice from death even when they are given 1 or 2 days after the infection (11, 32, 35, 47). Although the mechanism of action is not clearly understood, immunoglobulin G antibodies may participate in antibody-dependent cellular cytotoxicity and antibody-dependent complement-mediated cytolysis (33, 47). Antibodies could also neutralize the infectivity of the virus released from dying cells, thereby preventing local and distant virus dissemination (28). In vitro studies revealed that pretreatment of herpesviruses with SLS decreased in a concentration-dependent manner their infectivities for Vero cells. Ward and Ashley have already reported that SLS inactivates rotavirus at concentrations that are quite low and under very mild conditions (58). Most of the proteins of the outer shell remained associated with the virions, and the decreased adsorption may be an electrostatic effect due to the adsorption of SLS molecules on the virus surface (57). Recently, Howett et al. (24) have reported that SLS is a potent inactivator of HSV-2, human immunodeficiency virus, and human papillomaviruses. In that study, it was suggested that SLS denatures the capsid proteins of nonenveloped viruses, while both envelope disruption and denaturation of virus structural proteins occurred for enveloped viruses. Previous studies from our laboratory also showed that SLS is a potent inactivator of the infectivities of HSV-1, HSV-2, and human immunodeficiency virus type 1 strains (42). SLS did not interfere with the binding of HSV-1 to Vero cells, but viruses were able to enter cells and to produce capsid shells devoid of a DNA core in the nuclei. The amount of the glycoprotein D gene produced in these cells remained unchanged compared to the amount produced in control cells, suggesting that SLS could interfere with the maturation of the virus. Our results showed that SLS inhibited the HSV-1 strain F-induced cytopathic effect in Vero cells probably by affecting newly synthesized viruses that come into contact with the SLS present in culture medium following their release from cells, therefore preventing a productive infection of new cells. Combination of foscarnet and SLS resulted in a subsynergistic to substantagonistic effect. Toxicity studies with Vero cells confirmed that the inhibitory effect observed was due to the effects of the tested compounds on the virus itself rather than on the cells.

Foscarnet in PBS decreased in a concentration-dependent manner the viabilities of cultured human skin fibroblasts. Aleanius et al. (1) have reported that treatment of guinea pigs with a 3% foscarnet cream once daily for 4 days caused transient skin irritation in some animals. In addition, foscarnet excreted in the urine caused ulcerations of mucous membranes in the genital area (54). Our results have demonstrated that the gel has a protective effect against the toxicity of foscarnet. This suggests that the incorporation of foscarnet into the polymer formulation could reduce the apparition of irritations and ulcerations following topical administration of this drug. Gagné et al. reported a similar reduction of the toxicity of nonoxynol-9, a nonionic surfactant, for human cervical and colon epithelial cells as well as for the vaginal mucosa of rabbits following its incorporation into this polymer matrix (22). On the other hand, our results showed that 10% SLS incorporated in buffer or SLS in the gel formulation was nontoxic to human skin fibroblasts. The nontoxicity of SLS for cultured cells is supported by the fact that shampoos and toothpastes that contain 5 to 10% SLS are nontoxic for skin and/or mucosal surfaces.

In conclusion, our results showed that the incorporation of SLS into a polymer matrix composed of polyoxypropylene and polyoxylethylene containing foscarnet increased the efficacy of this drug administered topically and could represent a suitable formulation for the treatment of cutaneous or genital herpes infections, especially those caused by acyclovir-resistant strains. The incorporation of foscarnet into the gel formulation may also reduce the potential risks of skin irritation or mucosal ulcerations associated with the topical administration of this antiviral agent.

ACKNOWLEDGMENTS

This study was supported by a grant from Infectio Recherche Inc. We thank Guy Boivin and Rabeea F. Omar for constructive comments and helpful discussions.

REFERENCES
